遗传多态性和白金诱导的血液毒性:一个系统的审查
Yi Zheng1, Mimi Tang2, Zheng Deng3,4
1Hunan Provincial Maternal and Child Health Care Hospital, Changsha, China.
Frontiers in pharmacology
|September 5, 2024
概括
本综述确定了白金诱导的血液毒性的遗传生物标志物,突出了像GSTP1 rs1695和ERCC1 rs11615.5这样的有希望的变体. 由于结果不一致和方法限制,需要进一步验证.
科学领域:
- 药物基因组学 药物基因组学
- 在瘤学瘤学.
- 临床遗传学 临床遗传学
背景情况:
- 基于的化疗会引起严重的血液毒性,影响治疗的坚持.
- 遗传变异可能会影响这种毒性,但现有的研究是有争议的,缺乏全面的审查.
- 识别可靠的遗传生物标志物对于个性化癌症治疗至关重要.
研究的目的:
- 在癌症患者中系统地审查和识别与诱导的血液毒性相关的遗传生物标志物.
- 提供当前证据的概述,并突出潜在的遗传标记,以便进一步调查.
主要方法:
- 在PubMed,Embase和Web of Science数据库中的系统文献搜索,截至2022年1月28日.
- 包括评估遗传变异和与相关的血液毒性研究的研究,具有定义的终点和评分系统.
- 使用STREGA检查清单和结果叙事综合的质量评估.
主要成果:
- 分析了83项研究,检查了110个基因的682多个单核酸多态 (SNP).
- 发现了不一致的发现和方法问题 (小样本大小,不同的终点).
- 10个基因中的11个SNP在多个种群中显示出一致的结果,其中GSTP1 rs1695,ERCC1 rs11615,ERCC1 rs3212986和XRCC1 rs25487是最有希望的.
结论:
- 几种遗传变异显示出诱导的血液毒性生物标志物的潜力.
- 方法上的局限性需要在更大,更精心设计的研究中进行验证.
- 未来的研究应该专注于用于确定生物标志物识别的强大方法.
相关概念视频
01:27Principles of Pharmacogenetics: Types of Genetic Variants
143
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
143
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
01:27Pharmacogenetics of Drug Metabolism: Overview
195
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
195
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
100
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
100
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
01:16Drug toxicity: Idiosyncratic Reactions
232
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
232